Literature DB >> 15868769

Medicaid managed care: disparities in the use of thiazolidinediones compared with metformin.

Fadia T Shaya1, James Y Shin, Daniel Mullins, Hugh O Fatodu, Anna Gu, Elijah Saunders.   

Abstract

OBJECTIVE: To identify patient characteristics that are associated with the incidence of thiadolidinediones (TZDs) or metformin prescnbing in Medicaid managed care plans. RESEARCH DESIGN AND METHODS: We utilized a retrospective cohort study design. Two-and-one-half years of prescription claims of Medicaid managed care organizations (MCOs) patients who were new utilizers of metformin or TZDs were analyzed using univariate, bivariate and multivariate models. Multivariate logistic regression models were built to assess the combined effect of all variables on the likelihood of incident use of TZDs or metformin.
RESULTS: Claims for 3,041 patients were analyzed for the period between January 15, 2000 and June 15, 2002. African Americans and urban residents were less likely to be started on TZDs (OR = 0.678, 95% C1 = 0.830-1.206; OR = 0.579, 95% CI = 0.479-0.699, respectively). Advanced age, preexisting comorbidities and diabetes complications, and prior use of other oral diabetes drugs or insulin were predictors of increased likelihood of TZD initiation.
CONCLUSIONS: Race, age, residential setting, preexisting comorbidities and diabetes complications, other oral diabetes drug use, and insulin use are statistically significant predictors of initial prescribing of TZD or metformin in a Medicaid MCO population. Findings can potentially inform the management of diabetes in managed care so as to improve outcomes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15868769      PMCID: PMC2568710     

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN: 0027-9684            Impact factor:   1.798


  15 in total

Review 1.  Current oral agents for type 2 diabetes. Many options, but which to choose when?

Authors:  Andrew J Ahmann; Matthew C Riddle
Journal:  Postgrad Med       Date:  2002-05       Impact factor: 3.840

Review 2.  Early detection of undiagnosed diabetes mellitus: a US perspective.

Authors:  M I Harris; R C Eastman
Journal:  Diabetes Metab Res Rev       Date:  2000 Jul-Aug       Impact factor: 4.876

3.  The prevention or delay of type 2 diabetes.

Authors:  Robert S Sherwin; Robert M Anderson; John B Buse; Marshall H Chin; David Eddy; Judith Fradkin; Theodore G Ganiats; Henry Ginsberg; Richard Kahn; Robin Nwankwo; Marion Rewers; Leonard Schlessinger; Michael Stern; Frank Vinicor; Bernard Zinman
Journal:  Diabetes Care       Date:  2003-01       Impact factor: 19.112

4.  Rosiglitazone monotherapy is effective in patients with type 2 diabetes.

Authors:  H E Lebovitz; J F Dole; R Patwardhan; E B Rappaport; M I Freed
Journal:  J Clin Endocrinol Metab       Date:  2001-01       Impact factor: 5.958

5.  A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients.

Authors:  J G Yu; Y T Kruszynska; M I Mulford; J M Olefsky
Journal:  Diabetes       Date:  1999-12       Impact factor: 9.461

6.  Contribution of major diseases to disparities in mortality.

Authors:  Mitchell D Wong; Martin F Shapiro; W John Boscardin; Susan L Ettner
Journal:  N Engl J Med       Date:  2002-11-14       Impact factor: 91.245

7.  Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes.

Authors:  Jeffrey A Johnson; Sumit R Majumdar; Scot H Simpson; Ellen L Toth
Journal:  Diabetes Care       Date:  2002-12       Impact factor: 19.112

Review 8.  Trends in end-stage renal disease. Epidemiology, morbidity, and mortality.

Authors:  S T Reikes
Journal:  Postgrad Med       Date:  2000-07       Impact factor: 3.840

9.  Thiazolidinedione-associated congestive heart failure and pulmonary edema.

Authors:  Asra Kermani; Abhimanyu Garg
Journal:  Mayo Clin Proc       Date:  2003-09       Impact factor: 7.616

10.  Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes.

Authors:  Suzanne M Strowig; M Larissa Avilés-Santa; Philip Raskin
Journal:  Diabetes Care       Date:  2002-10       Impact factor: 19.112

View more
  3 in total

1.  Utilizing new prescription drugs: disparities among non-Hispanic whites, non-Hispanic blacks, and Hispanic whites.

Authors:  Junling Wang; Ilene H Zuckerman; Nancy A Miller; Fadia T Shaya; Jason M Noel; C Daniel Mullins
Journal:  Health Serv Res       Date:  2007-08       Impact factor: 3.402

2.  Race and medication adherence in Medicaid enrollees with type-2 diabetes.

Authors:  Rahul A Shenolikar; Rajesh Balkrishnan; Fabian T Camacho; J Timothy Whitmire; Roger T Anderson
Journal:  J Natl Med Assoc       Date:  2006-07       Impact factor: 1.798

3.  Agreement between self-reported and administrative race and ethnicity data among Medicaid enrollees in Minnesota.

Authors:  Donna D McAlpine; Timothy J Beebe; Michael Davern; Kathleen T Call
Journal:  Health Serv Res       Date:  2007-12       Impact factor: 3.402

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.